Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement within targeted cancer care. This innovative antibody-drug conjugate pairs a monoclonal antigen specifically focused on HER2 positive expressing cells with a potent cytotoxic payload, deruxtecan. The mechanism of action involves the antibody's ability to attach